Biogen received marketing approval from the European Commission for Spinraza (nusinersen), its treatment for spinal muscular atrophy (SMA), in May of last year but has struggled to generate access across Europe.
One step towards improving patients’ access to the treatment was announced with Biogen announcing that NICE had agreed to evaluate the treatment through its Single Technology Appraisal (STA) route.
